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 Wasting is prevalent among patients with 
chronic kidney disease (CKD). Eighteen to 
seventy-fi ve percent of adults with end-stage 
renal disease undergoing maintenance 
dialysis showed some evidence of wasting. 
Wasting has been closely associated with 
mortality and morbidity in patients with 
CKD. Although inadequate nutritional 
intake may contribute to wasting, recent evi-
dence indicates that other factors, including 
systemic infl ammation, perturbations of 
appetite-controlling hormones from reduced 
renal clearance, aberrant neuropeptide sig-
naling, insulin and insulin-like growth factor 
(IGF) resistance, and metabolic acidosis, 
may be important in the pathogenesis of 
CKD-associated wasting. 1 – 5 
 Th e pathophysiology of muscle wasting 
in CKD involves complex mechanisms 
(Figure 1). 4 Identifi ed mediators of muscle 
protein breakdown in CKD include infl am-
mation, metabolic acidosis, angiotensin II, 
and neural and hormonal factors that 
cause defects in insulin / IGF-I intracellular 
signaling processes. Abnormalities in 
insulin / IGF-I signaling activate muscle pro-
tein degradation in the adenosine triphos-
phate-dependent ubiquitin – proteasome 
system. Th is multi-enzyme system involves 
the targeting of muscle proteins by a series 
of enzymatic reactions and the subsequent 
degradation by a large protein complex 
called the proteasome. Proteins are targeted 
for proteasomal degradation by the covalent 
attachment of polymeric chains of a 7-kDa 
protein, ubiquitin, to the   -amino group of 
lysine residues in the substrate proteins. Th e 
key substrate recognition component in this 
process is a group of enzymes called E3 
ubiquitin ligases, which are the largest 
known family of functionally related pro-
teins in mammals. Once the substrate pro-
tein is  ‘ polyubiquitinated, ’ it is degraded by 
the proteasome, a large (2000 kDa) multi-
subunit complex found in all mammalian 
cells. In muscle, when the atrophy process 
is initiated, genes encoding forkhead box 
O1 (FoxO1) transcription factor and two 
muscle-specifi c E3 ligases, Atrogin-1 (also 
known as MAFbx) and muscle-specifi c ring 
fi nger-1 (MuRF-1), as well as ubiquitin and 
a select group of proteasome subunits are 
upregulated. 4,5 Th is process occurs uniquely 
in skeletal muscle cells. FoxO is a class 
of transcription factors, a subfamily of 
the large group of forkhead transcription 
factors. Mammalian cells contain three 
members of this family, FoxO1, FoxO3, and 
FoxO4. 6 AKT blocks the function of all 
three by phosphorylation of three conserved 
residues, leading to their sequestration in 
the cytoplasm away from target genes. Reed 
and colleagues tested the physiological signi-
fi cance of FoxO activation in the progres-
sion of muscle atrophy associated with 
cancer cachexia and sepsis. 7 Transcription 
dependent on FoxO – DNA binding was 
blocked in the muscles of mice through 
injection of a dominant-negative FoxO 
expression plasmid prior to inoculation 
with Lewis lung carcinoma cells or the 
induction of sepsis. Dominant-negative 
FoxO inhibited the increased mRNA levels 
of Atrogin-1 and MuRF-1 and inhibited 
muscle fi ber atrophy during cancer cachexia 
and sepsis. Interestingly, dominant-negative 
FoxO also decreased myostatin expression, 
increased MyoD expression and satellite-
cell proliferation, and induced fi ber hyper-
trophy, which required  de novo protein 
synthesis. Th ese data show that transcrip-
tion dependent on FoxO – DNA binding is 
an important mechanism for muscle wast-
ing during cancer cachexia and sepsis, and 
further suggest that basal levels of FoxO 
play an important physiological role to 
regulate satellite-cell activation and muscle 
growth. 7 
 Xu and colleagues 8 (this issue) showed 
that CKD did not lead to muscle wasting in 
mice with muscle-specific knockout of 
FoxO1 by  cre / lox methodology. Protein 
degradation and expression of the ubiqui-
tin ligases Atrogin-1 and MuRF-1, which 
were known to be upregulated in CKD 
(Figure 1), were not changed in the mice 
with muscle-specific FoxO1 knockout 
despite the induction of CKD, when com-
pared with values in the  lox / lox control 
mice. Then, these authors showed that 
transfection of microRNA-486 (miR-486) 
into primary cultures of myotubes down-
regulated FoxO1 and its translation via 
decreased phosphatase and tensin homolog 
(PTEN) activity, which in turn negatively 
regulated phospho-protein kinase B (Akt). 
miR-486 mimetic blocked dexamethasone-
stimulated protein degradation without 
influencing protein synthesis. Finally, 
these investigators showed that  in vivo 
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electroporation of miR-486 into muscles 
prevented the Atrogin-1 and MuRF-1 
upregulation and muscle wasting in mice 
with CKD. 8 
 miRs are a class of post-transcriptional 
regulators that have recently introduced an 
additional level of intricacy to our under-
standing of gene regulation. Currently, 
more than 10,000 miRs have been identi-
fi ed in a range of species, including meta-
zoa, mycetozoa, viridiplantae, and viruses, 
of which 940, to date, are found in humans. 
It is estimated that more than 60 % of 
human protein-coding genes harbor miR 
target sites in their 3  -untranslated region 
and, thus, are potentially regulated by 
these molecules in health and disease. 
They are small RNA molecules that 
post-transcriptionally regulate gene 
expression and have been shown to play 
an important role during development. 
miR-1, miR-133a, miR-133b, and miR-206 
are expressed in muscle tissue and induced 
during muscle-cell diff erentiation, a proc-
ess that directs myoblasts to diff erentiate 
into mature myotubes, which are organ-
ized into myofi bers. 9 
 Wang and colleagues recently exam-
ined a profi le of miRs in muscles from 
mice with CKD and observed downregu-
lation of both miR-29a and miR-29b. 10 
Because miR-29 has a complementary 
sequence to the 3  -untranslated region of 
Ying Yang-1 mRNA, a decrease in miR-29 
could increase Ying Yang-1, a myogene-
sis-suppressing transcription factor that 
was indeed upregulated in skeletal mus-
cles in CKD. These investigators then 
used adenovirus-mediated gene transfer 
to express miR-29 in C2C12 myoblasts 
and measured its effect on both Ying 
Yang-1 and myoblast diff erentiation. An 
increase in miR-29 decreased the abun-
dance of Ying Yang-1 and improved the 
diff erentiation of myoblasts into myo-
tubes. Similarly, with the use of myoblasts 
isolated from muscles of mice with CKD, 
an increase in miR-29 improved diff eren-
tiation of muscle progenitor cells into 
myotubes. Th e authors concluded that 
CKD suppresses miR-29 in muscle, which 
leads to higher expression of the tran-
scription factor Ying Yang-1, thereby 
suppressing myogenesis. 10 
 The novel results from Xu and col-
leagues 8 suggest that pharmacological 
agents that target FoxO1 could potentially 
be developed into therapeutic agents for 
muscle wasting. Furthermore, miR-486 
and other miRs involved in muscle mass 
regulation (Figure 1) are also potential 
therapeutic targets. Th e  in vivo electropo-
ration route of delivery of miR-486 into 
muscles used in the present study is 
unlikely to be useful in humans. Other 
less invasive delivery methods need to be 
developed and tested in clinical trials, in 
terms of both effi  cacy and safety. Targets 
need to be skeletal muscle-specifi c, since 
undesirable side eff ects involving smooth 
muscles and, more importantly, cardiac 
muscles may prove problematic or even 
fatal. Nevertheless, these exciting proof-
of-principle data do show that miR 
mimetics represent a new therapeutic 
frontier for muscle wasting, a prevalent 
and important complication that is associ-
ated with increased mortality and mor-
bidity in patients with CKD and end-stage 
renal disease. 
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 Figure 1  |  Pathophysiology and potential therapeutic role of microRNA in muscle wasting 
in chronic kidney disease. The diagram displays different microRNAs (miRs) and their potential 
targets that have been implicated in the pathogenesis of muscle wasting in chronic kidney disease. 
Upregulation and downregulation of a gene are represented by  ‘  +  ’ and  ‘  ’, respectively. 
